Detection of antibodies against glucose 6-phosphate isomerase in synovial fluid of rheumatoid arthritis using surface plasmon resonance (BIAcore).
- Author:
Ji Yeon KIM
1
;
Mi Hong LEE
;
Kyung In JUNG
;
Hye Young NA
;
Hoon Suk CHA
;
Eun Mi KO
;
Tae Jin KIM
Author Information
1. Department of Pathology and Center for Molecular Medicine, Samsung Biomedical Research Institute, School of Medicine, Sungkyunkwan University, Suwon 440-746, Korea. tjkim@med.skku.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
autoimmune disease;
biosensing techniques;
glucose 6-phosphate isomerase;
rheumatoid arthritis;
Serology
- MeSH:
Aged;
Antibodies/*immunology;
Arthritis, Rheumatoid/*immunology;
Female;
Glucose-6-Phosphate Isomerase/genetics/*immunology/metabolism;
Human;
Male;
Middle Aged;
Osteoarthritis/immunology;
Peptide Elongation Factors/genetics/metabolism;
Recombinant Fusion Proteins/genetics/metabolism;
Surface Plasmon Resonance;
Synovial Fluid/*immunology;
Transcription Factors/genetics/metabolism
- From:Experimental & Molecular Medicine
2003;35(4):310-316
- CountryRepublic of Korea
- Language:English
-
Abstract:
We have used a surface plasmon resonance biosensor (SPR, BIACORE 2000) to detect antibodies against glucose 6-phosphate isomerase (GPI) in synovial fluids of rheumatoid arthritis (RA) and osteoarthritis (OA). Recombinant human GPI proteins fused with or without NusA were expressed in E. coli, purified to homogeneity and immobilized in flow cells of CM5 sensor chips. The flow cells immobilized with NusA protein or bovine serum albumin were used to monitor non-specific binding. Synovial fluid samples from RA patients showed a significantly higher level of binding to recombinant GPI proteins than samples from OA patients. Proteins which bound to the recombinant GPI proteins were confirmed to be immunoglobulin through the administration of anti-human immunoglobulin. NusA fusion protein was excellent for this assay because of a low background binding activity in the SPR analysis and its advantage of increased solubility in recombinant protein production. These results suggested a useful utilization of recombinant NusA-GPI fusion protein for the detection of autoantibodies against GPI in RA patients.
